Metilfenidato (Portuguese Wikipedia)

Foquest: Methylphenidate hydrochloride controlled release capsules (PDF) (vers. E). Product Monograph. Pickering, Ontario, Canada: Purdue Pharma. 1 de março de 2019. Submission Control Nr 214860. Consultado em 14 de dezembro de 2022 – via caddra.ca

comlaw.gov.au

«Poisons Standard 2012 as amended made under paragraph 52D(2)(a) of the Therapeutic Goods Act 1989». Therapeutic Goods Administration. 27 de novembro de 2014. Consultado em 28 de junho de 2015. Cópia arquivada em 1 de julho de 2015

doi.org

dx.doi.org

Bushe C, Day K, Reed V, Karlsdotter K, Berggren L, Pitcher A, Televantou F, Haynes V (maio de 2016). «A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients». Journal of Psychopharmacology. 30 (5): 444–458. PMID 27005307. doi:10.1177/0269881116636105
Hazell PL, Kohn MR, Dickson R, Walton RJ, Granger RE, Wyk GW (novembro de 2011). «Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis». Journal of Attention Disorders. 15 (8): 674–683. PMID 20837981. doi:10.1177/1087054710379737
Hanwella R, Senanayake M, de Silva V (novembro de 2011). «Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis». BMC Psychiatry. 11 (1). 176 páginas. PMC 3229459. PMID 22074258. doi:10.1186/1471-244X-11-176
Stuhec M, Lukić P, Locatelli I (fevereiro de 2019). «Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis». The Annals of Pharmacotherapy. 53 (2): 121–133. PMID 30117329. doi:10.1177/1060028018795703
Faraone SV, Pliszka SR, Olvera RL, Skolnik R, Biederman J (junho de 2001). «Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a reanalysis using drug-placebo and drug-drug response curve methodology». Journal of Child and Adolescent Psychopharmacology. 11 (2): 171–180. PMID 11436957. doi:10.1089/104454601750284081. ProQuest 204600452
Faraone SV, Biederman J, Roe C (outubro de 2002). «Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis». Journal of Clinical Psychopharmacology. 22 (5): 468–473. PMID 12352269. doi:10.1097/00004714-200210000-00005
Faraone SV, Buitelaar J (abril de 2010). «Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis». European Child & Adolescent Psychiatry. 19 (4): 353–364. PMID 19763664. doi:10.1007/s00787-009-0054-3
Arnsten AF, Li BM (2005). «Neurobiology of Executive Functions: Catecholamine Influences on Prefrontal Cortical Functions». Biological Psychiatry. 57: 1377–84. PMID 15950011. doi:10.1016/j.biopsych.2004.08.019
Fone KC, Nutt DJ (2005). «Stimulants: use and abuse in the treatment of ADD». Current Opinion in Pharmacology. 5 (1): 87–93. PMID 15661631. doi:10.1016/j.coph.2004.10.001
Capp PK, Pearl PL, Conlon C (2005). «Methylphenidate HCl: therapy for attention deficit hyperactivity disorder». Expert Rev Neurother. 5 (3): 325–31. PMID 15938665. doi:10.1586/14737175.5.3.325
Greenfield B, Hechman L (2005). «Treatment of attention deficit hyperactivity disorder in adults». Expert Rev Neurother. 5 (1): 107–21. PMID 15853481. doi:10.1586/14737175.5.1.107
Huss, Michael; Duhan, Praveen; Gandhi, Preetam; Chen, Chien-Wei; Spannhuth, Carsten; Kumar, Vinod (2 de junho de 2021). «Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity». Neuropsychiatric Disease and Treatment. 13: 1741–1751. PMC 5505611. PMID 28740389. doi:10.2147/NDT.S130444
Gilmore A, Milne R (2001). «Methylphenidate in children with hyperactivity: review and cost-utility analysis». Pharmacoepidemiol Drug Saf. 10 (2): 85–94. PMID 11499858. doi:10.1002/pds.564
Huang YS, Tsai MH (julho de 2011). «Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge». CNS Drugs. 25 (7): 539–554. PMID 21699268. doi:10.2165/11589380-000000000-00000
Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C (novembro de 2015). «Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)» (PDF). Cochrane Database Syst Rev. 11 (11): CD009885. PMID 26599576. doi:10.1002/14651858.CD009885.pub2. the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects.
Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S (fevereiro de 2002). «Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults». J. Am. Acad. Child Adolesc. Psychiatry. 41 (2 Suppl): 26S–49S. PMID 11833633. doi:10.1097/00004583-200202001-00003
Faraone SV, Wilens TE (2007). «Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion». J Clin Psychiatry. 68 Suppl 11 (11): 15–22. PMID 18307377. doi:10.4088/jcp.1107e28
Wilens TE, Faraone SV, Biederman J, Gunawardene S (2003). «Does Stimulant Therapy of Attention-Deficit/Hyperactivity Disorder Beget Later Substance Abuse? A Meta-analytic Review of the Literature». Pediatrics. 111 (1): 179–85. CiteSeerX 10.1.1.507.874. PMID 12509574. doi:10.1542/peds.111.1.179
Abelman DD (outubro de 2017). «Mitigating risks of students use of study drugs through understanding motivations for use and applying harm reduction theory: a literature review». Harm Reduction Journal. 14 (1). 68 páginas. PMC 5639593. PMID 28985738. doi:10.1186/s12954-017-0194-6
Vitiello B (outubro de 2001). «Psychopharmacology for young children: clinical needs and research opportunities». Pediatrics. 108 (4): 983–9. PMID 11581454. doi:10.1542/peds.108.4.983
Hermens DF, Rowe DL, Gordon E, Williams LM (2006). «Integrative neuroscience approach to predict ADHD stimulant response». Expert Review of Neurotherapeutics. 6 (5): 753–63. PMID 16734523. doi:10.1586/14737175.6.5.753
Management (1 de novembro de 2011). «ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents». Pediatrics. 128 (5): 1007–1022. ISSN 0031-4005. PMC 4500647. PMID 22003063. doi:10.1542/peds.2011-2654
Fry JM (fevereiro de 1998). «Treatment modalities for narcolepsy». Neurology. 50 (2 Suppl 1): S43-8. PMID 9484423. doi:10.1212/WNL.50.2_Suppl_1.S43
Mitler MM (dezembro de 1994). «Evaluation of treatment with stimulants in narcolepsy». Sleep. 17 (8 Suppl): S103-6. PMID 7701190. doi:10.1093/sleep/17.suppl_8.S103
Hart, Heledd; Radua, Joaquim; Nakao, Tomohiro; Mataix-Cols, David; Rubia, Katya (fevereiro de 2013). «Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects». JAMA psychiatry. 70 (2): 185–198. ISSN 2168-6238. PMID 23247506. doi:10.1001/jamapsychiatry.2013.277
Spencer, Thomas J.; Brown, Ariel; Seidman, Larry J.; Valera, Eve M.; Makris, Nikos; Lomedico, Alexandra; Faraone, Stephen V.; Biederman, Joseph (setembro de 2013). «Effect of Psychostimulants on Brain Structure and Function in ADHD: A Qualitative Literature Review of MRI-Based Neuroimaging Studies». The Journal of clinical psychiatry. 74 (9): 902–917. ISSN 0160-6689. PMC 3801446. PMID 24107764. doi:10.4088/JCP.12r08287
Frodl, T.; Skokauskas, N. (2012). «Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects». Acta Psychiatrica Scandinavica (em inglês). 125 (2): 114–126. ISSN 1600-0447. PMID 22118249. doi:10.1111/j.1600-0447.2011.01786.x
Schweren, Lizanne J. S.; de Zeeuw, Patrick; Durston, Sarah (1 de outubro de 2013). «MR imaging of the effects of methylphenidate on brain structure and function in Attention-Deficit/Hyperactivity Disorder». European Neuropsychopharmacology. 23 (10): 1151–1164. ISSN 0924-977X. doi:10.1016/j.euroneuro.2012.10.014
Markowitz JS, Patrick KS (junho de 2008). «Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: Does chirality matter?». Journal of Clinical Psychopharmacology. 28 (3 Suppl 2): S54–S61. PMID 18480678. doi:10.1097/JCP.0b013e3181733560
Williard RL, Middaugh LD, Zhu HJ, Patrick KS (fevereiro de 2007). «Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity». Behavioural Pharmacology. 18 (1): 39–51. PMID 17218796. doi:10.1097/fbp.0b013e3280143226
Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R (dezembro de 2006). «A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study». Journal of Child and Adolescent Psychopharmacology. 16 (6): 687–698. PMID 17201613. doi:10.1089/cap.2006.16.687
Markowitz JS, Logan BK, Diamond F, Patrick KS (1999). «Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion». Journal of Clinical Psychopharmacology. 19 (4): 362–6. PMID 10440465. doi:10.1097/00004714-199908000-00013
Markowitz JS, Logan BK, Diamond F, Patrick KS (1999). «Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion». Journal of Clinical Psychopharmacology. 19 (4): 362–6. PMID 10440465. doi:10.1097/00004714-199908000-00013
Iversen L (janeiro de 2006). «Neurotransmitter transporters and their impact on the development of psychopharmacology». British Journal of Pharmacology. 147 (Suppl 1): S82–S88. PMC 1760736. PMID 16402124. doi:10.1038/sj.bjp.0706428
Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (1 de janeiro de 2002). «Mechanism of action of methylphenidate: insights from PET imaging studies». Journal of Attention Disorders. 6 (Suppl 1): S31–S43. PMID 12685517. doi:10.1177/070674370200601s05
Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (1 de janeiro de 2002). «Mechanism of action of methylphenidate: insights from PET imaging studies». Journal of Attention Disorders. 6 (Suppl 1): S31–S43. PMID 12685517. doi:10.1177/070674370200601s05
Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (1 de janeiro de 2002). «Mechanism of action of methylphenidate: insights from PET imaging studies». Journal of Attention Disorders. 6 (Suppl 1): S31–S43. PMID 12685517. doi:10.1177/070674370200601s05
Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (1 de janeiro de 2002). «Mechanism of action of methylphenidate: insights from PET imaging studies». Journal of Attention Disorders. 6 (Suppl 1): S31–S43. PMID 12685517. doi:10.1177/070674370200601s05
Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (1 de janeiro de 2002). «Mechanism of action of methylphenidate: insights from PET imaging studies». Journal of Attention Disorders. 6 (Suppl 1): S31–S43. PMID 12685517. doi:10.1177/070674370200601s05
Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (1 de janeiro de 2002). «Mechanism of action of methylphenidate: insights from PET imaging studies». Journal of Attention Disorders. 6 (Suppl 1): S31–S43. PMID 12685517. doi:10.1177/070674370200601s05
Volz TJ (dezembro de 2008). «Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidate». Current Neuropharmacology. 6 (4): 379–385. PMC 2701286. PMID 19587858. doi:10.2174/157015908787386041
Kimko HC, Cross JT, Abernethy DR (dezembro de 1999). «Pharmacokinetics and clinical effectiveness of methylphenidate». Clinical Pharmacokinetics. 37 (6): 457–470. PMID 10628897. doi:10.2165/00003088-199937060-00002
Chan YP, Swanson JM, Soldin SS, Thiessen JJ, Macleod SM, Logan W (julho de 1983). «Methylphenidate hydrochloride given with or before breakfast: II. Effects on plasma concentration of methylphenidate and ritalinic acid». Pediatrics. 72 (1): 56–59. PMID 6866592. doi:10.1542/peds.72.1.56. Consultado em 12 de dezembro de 2021. Cópia arquivada em 17 de dezembro de 2021
Lee L, Kepple J, Wang Y, Freestone S, Bakhtiar R, Wang Y, Hossain M (setembro de 2003). «Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce». Biopharmaceutics & Drug Disposition. 24 (6): 233–243. PMID 12973820. doi:10.1002/bdd.358
Lee L, Kepple J, Wang Y, Freestone S, Bakhtiar R, Wang Y, Hossain M (setembro de 2003). «Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce». Biopharmaceutics & Drug Disposition. 24 (6): 233–243. PMID 12973820. doi:10.1002/bdd.358
Nutt D, King LA, Saulsbury W, Blakemore C (março de 2007). «Development of a rational scale to assess the harm of drugs of potential misuse». Lancet. 369 (9566): 1047–1053. PMID 17382831. doi:10.1016/S0140-6736(07)60464-4
Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M (setembro de 2013). «Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies». Springer Science and Business Media LLC. BMC Psychiatry. 13 (1): 237. PMC 3852277. PMID 24074240. doi:10.1186/1471-244x-13-237
Ross DC, Fischhoff J, Davenport B (janeiro de 2002). «Treatment of ADHD when tolerance to methylphenidate develops». Psychiatric Services. 53 (1). 102 páginas. PMID 11773663. doi:10.1176/appi.ps.53.1.102
Peterson BS, Trampush J, Maglione M, Bolshakova M, Rozelle M, Miles J, Pakdaman S, Brown M, Yagyu S, Motala A, Hempel S (abril de 2024). «Treatments for ADHD in Children and Adolescents: A Systematic Review». Pediatrics. 153 (4). PMID 38523592 Verifique |pmid= (ajuda). doi:10.1542/peds.2024-065787
Bron TI, Bijlenga D, Kasander MV, Spuijbroek AT, Beekman AT, Kooij JJ (junho de 2013). «Long-term relationship between methylphenidate and tobacco consumption and nicotine craving in adults with ADHD in a prospective cohort study». European Neuropsychopharmacology. 23 (6): 542–554. PMID 22809706. doi:10.1016/j.euroneuro.2012.06.004
Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Graham J, Taylor E, Sergeant J (março de 2013). «Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents». Journal of Child Psychology and Psychiatry, and Allied Disciplines. 54 (3): 227–246. PMID 23294014. doi:10.1111/jcpp.12036
Poulton A (agosto de 2005). «Growth on stimulant medication; clarifying the confusion: a review». Archives of Disease in Childhood. 90 (8): 801–806. PMC 1720538. PMID 16040876. doi:10.1136/adc.2004.056952
Hinshaw SP, Arnold LE (janeiro de 2015). «ADHD, Multimodal Treatment, and Longitudinal outcome: Evidence, paradox, and challenge». Wiley Interdisciplinary Reviews. Cognitive Science. 6 (1): 39–52. PMC 4280855. PMID 25558298. doi:10.1002/wcs.1324
Findling RL, Dinh S (março de 2014). «Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS)». CNS Drugs. 28 (3): 217–228. PMC 3933749. PMID 24532028. doi:10.1007/s40263-014-0141-y
Kraemer M, Uekermann J, Wiltfang J, Kis B (julho de 2010). «Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature». Clinical Neuropharmacology. 33 (4): 204–206. PMID 20571380. doi:10.1097/WNF.0b013e3181e29174
«FDA drug safety communication: Safety review update of medications used to treat attention-deficit / hyperactivity disorder (ADHD) in children and young adults». U.S. Food and Drug Administration (FDA). 20 de dezembro de 2011. Consultado em 4 de novembro de 2013. Cópia arquivada em 30 de outubro de 2013 Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA (novembro de 2011). «ADHD drugs and serious cardiovascular events in children and young adults». The New England Journal of Medicine. 365 (20): 1896–1904. PMC 4943074. PMID 22043968. doi:10.1056/NEJMoa1110212 «FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults». U.S. Food and Drug Administration (FDA). 15 de dezembro de 2011. Consultado em 4 de novembro de 2013. Cópia arquivada em 30 de outubro de 2013 Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV (dezembro de 2011). «ADHD medications and risk of serious cardiovascular events in young and middle-aged adults». JAMA. 306 (24): 2673–2683. PMC 3350308. PMID 22161946. doi:10.1001/jama.2011.1830
Gordon N (1999). «Attention deficit hyperactivity disorder: Possible causes and treatment». International Journal of Clinical Practice. 53 (7): 524–528. PMID 10692738. doi:10.1111/j.1742-1241.1999.tb11794.x
Storebø OJ, Pedersen N, Ramstad E, Kielsholm ML, Nielsen SS, Krogh HB, Moreira-Maia CR, Magnusson FL, Holmskov M, Gerner T, Skoog M, Rosendal S, Groth C, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Håkonsen SJ, Aagaard L, Simonsen E, Gluud C (maio de 2018). «Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies». The Cochrane Database of Systematic Reviews (Systematic Review). 5 (5): CD012069. PMC 6494554. PMID 29744873. doi:10.1002/14651858.CD012069.pub2
Spiller HA, Hays HL, Aleguas A (julho de 2013). «Overdose of drugs for attention-deficit hyperactivity disorder: Clinical presentation, mechanisms of toxicity, and management». CNS Drugs. 27 (7): 531–543. PMID 23757186. doi:10.1007/s40263-013-0084-8
Bruggisser M, Bodmer M, Liechti ME (2011). «Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets». Swiss Medical Weekly. 141: w13267. PMID 21984207. doi:10.4414/smw.2011.13267
Morton WA, Stockton GG (outubro de 2000). «Methylphenidate Abuse and Psychiatric Side Effects». Primary Care Companion to the Journal of Clinical Psychiatry. 2 (5): 159–164. PMC 181133. PMID 15014637. doi:10.4088/PCC.v02n0502
Auger RR, Goodman SH, Silber MH, Krahn LE, Pankratz VS, Slocumb NL (junho de 2005). «Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: A case-control study». Sleep. 28 (6): 667–672. PMID 16477952. doi:10.1093/sleep/28.6.667
Auger RR, Goodman SH, Silber MH, Krahn LE, Pankratz VS, Slocumb NL (junho de 2005). «Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: A case-control study». Sleep. 28 (6): 667–672. PMID 16477952. doi:10.1093/sleep/28.6.667
Ishii M, Tatsuzawa Y, Yoshino A, Nomura S (abril de 2008). «Serotonin syndrome induced by augmentation of SSRI with methylphenidate». Psychiatry and Clinical Neurosciences. 62 (2). 246 páginas. PMID 18412855. doi:10.1111/j.1440-1819.2008.01767.x
Türkoğlu S (2015). «Serotonin syndrome with sertraline and methylphenidate in an adolescent». Clinical Neuropharmacology. 38 (2): 65–6. PMID 25768857. doi:10.1097/WNF.0000000000000075
Park YM, Jung YK (maio de 2010). «Manic switch and serotonin syndrome induced by augmentation of paroxetine with methylphenidate in a patient with major depression». Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34 (4): 719–20. PMID 20298736. doi:10.1016/j.pnpbp.2010.03.016
Bodner RA, Lynch T, Lewis L, Kahn D (fevereiro de 1995). «Serotonin syndrome». Neurology. 45 (2): 219–23. PMID 7854515. doi:10.1212/wnl.45.2.219
Israel, Joshua A. (10 de dezembro de 2015). «Combining Stimulants and Monoamine Oxidase Inhibitors: A Reexamination of the Literature and a Report of a New Treatment Combination». The Primary Care Companion for CNS Disorders. 17 (6). ISSN 2155-7772. PMC 4805402. PMID 27057401. doi:10.4088/PCC.15br01836
Shelton Clauson, Angela; Elliott, Ellie S.; Watson, Brian D.; Treacy, Journey (março de 2004). «Coadministration of phenelzine and methylphenidate for treatment-resistant depression». The Annals of Pharmacotherapy. 38 (3). 508 páginas. ISSN 1060-0280. PMID 14970373. doi:10.1345/aph.1D115
Thomas, Samantha J.; Shin, Mirae; McInnis, Melvin G.; Bostwick, Jolene R. (abril de 2015). «Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression». Pharmacotherapy. 35 (4): 433–449. ISSN 1875-9114. PMID 25884531. doi:10.1002/phar.1576
Patrick KS, González MA, Straughn AB, Markowitz JS (2005). «New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder». Expert Opinion on Drug Delivery. 2 (1): 121–43. PMID 16296740. doi:10.1517/17425247.2.1.121
Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, Malcolm R, Janis GC, Markowitz JS (março de 2007). «Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics.». Clinical Pharmacology and Therapeutics. 81 (3): 346–53. PMC 3188424. PMID 17339864. doi:10.1038/sj.clpt.6100082
Roberts SM, DeMott RP, James RC (1997). «Adrenergic modulation of hepatotoxicity». Drug Metab. Rev. 29 (1–2): 329–53. PMID 9187524. doi:10.3109/03602539709037587
Ruthirakuhan MT, Herrmann N, Abraham EH, Chan S, Lanctôt KL (maio de 2018). «Pharmacological interventions for apathy in Alzheimer's disease». Cochrane Database Syst Rev. 5 (5): CD012197. PMC 6494556. PMID 29727467. doi:10.1002/14651858.CD012197.pub2
Lee CW, Chen JY, Ko CC, Chuang MH, Tsai WW, Sun CK, Hung KC (dezembro de 2022). «Efficacy of methylphenidate for the treatment of apathy in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled studies». Psychopharmacology (Berl). 239 (12): 3743–3753. PMID 36243827. doi:10.1007/s00213-022-06261-y
Theleritis C, Siarkos K, Katirtzoglou E, Politis A (janeiro de 2017). «Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease : A systematic review across modalities». Journal of Geriatric Psychiatry and Neurology. 30 (1): 26–49. PMID 28248559. doi:10.1177/0891988716678684
Arnts H, van Erp WS, Lavrijsen JC, van Gaal S, Groenewegen HJ, van den Munckhof P (maio de 2020). «On the pathophysiology and treatment of akinetic mutism». Neurosci Biobehav Rev. 112: 270–278. PMID 32044373. doi:10.1016/j.neubiorev.2020.02.006
Rohde C, Polcwiartek C, Asztalos M, Nielsen J (janeiro de 2018). «Effectiveness of Prescription-Based CNS Stimulants on Hospitalization in Patients With Schizophrenia: A Nation-Wide Register Study». Schizophrenia Bulletin. 44 (1): 93–100. PMC 5768038. PMID 28379483. doi:10.1093/schbul/sbx043
Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J (2008). «Pharmacotherapy of methamphetamine addiction: an update». Substance Abuse. 29 (3): 31–49. PMC 2597382. PMID 19042205. doi:10.1080/08897070802218554
Grabowski J, Roache JD, Schmitz JM, Rhoades H, Creson D, Korszun A (dezembro de 1997). «Replacement medication for cocaine dependence: methylphenidate». Journal of Clinical Psychopharmacology. 17 (6): 485–488. PMID 9408812. doi:10.1097/00004714-199712000-00008
Shearer J (maio de 2008). «The principles of agonist pharmacotherapy for psychostimulant dependence». Drug and Alcohol Review. 27 (3): 301–308. PMID 18368612. doi:10.1080/09595230801927372
Villas-Boas CB, Chierrito D, Fernandez-Llimos F, Tonin FS, Sanches AC (março de 2019). «Pharmacological treatment of attention-deficit hyperactivity disorder comorbid with an anxiety disorder: a systematic review». Int Clin Psychopharmacol. 34 (2): 57–64. PMID 30422834. doi:10.1097/YIC.0000000000000243
Koyuncu A, İnce E, Ertekin E, Tükel R (2019). «Comorbidity in social anxiety disorder: diagnostic and therapeutic challenges». Drugs Context. 8. 212573 páginas. PMC 6448478. PMID 30988687. doi:10.7573/dic.212573
Pelissolo A, Abou Kassm S, Delhay L (dezembro de 2019). «Therapeutic strategies for social anxiety disorder: where are we now?». Expert Rev Neurother. 19 (12): 1179–1189. PMID 31502896. doi:10.1080/14737175.2019.1666713
Golubchik P, Sever J, Weizman A (julho de 2014). «Methylphenidate treatment in children with attention deficit hyperactivity disorder and comorbid social phobia». Int Clin Psychopharmacol. 29 (4): 212–215. PMC 4047304. PMID 24448460. doi:10.1097/YIC.0000000000000029
Koyuncu A, Çelebi F, Ertekin E, Kahn DA (maio de 2015). «Extended-release Methylphenidate Treatment and Outcomes in Comorbid Social Anxiety Disorder and Attention-deficit/Hyperactivity Disorder: 2 Case Reports». J Psychiatr Pract. 21 (3): 225–231. PMID 25955266. doi:10.1097/PRA.0000000000000070
Koyuncu A, Çelebi F, Ertekin E, Kök BE, Tükel R (novembro de 2017). «Extended-release methylphenidate monotherapy in patients with comorbid social anxiety disorder and adult attention-deficit/hyperactivity disorder: retrospective case series». Ther Adv Psychopharmacol. 7 (11): 241–247. PMC 5638159. PMID 29090087. doi:10.1177/2045125317714193
Koyuncu A, Çelebi F, Ertekin E, Kök BE, Tükel R (novembro de 2017). «Extended-release methylphenidate monotherapy in patients with comorbid social anxiety disorder and adult attention-deficit/hyperactivity disorder: retrospective case series». Ther Adv Psychopharmacol. 7 (11): 241–247. PMC 5638159. PMID 29090087. doi:10.1177/2045125317714193
Koyuncu A, Çelebi F, Ertekin E, Kök BE, Tükel R (novembro de 2017). «Extended-release methylphenidate monotherapy in patients with comorbid social anxiety disorder and adult attention-deficit/hyperactivity disorder: retrospective case series». Ther Adv Psychopharmacol. 7 (11): 241–247. PMC 5638159. PMID 29090087. doi:10.1177/2045125317714193
Koyuncu A, Çelebi F, Ertekin E, Kök BE, Tükel R (novembro de 2017). «Extended-release methylphenidate monotherapy in patients with comorbid social anxiety disorder and adult attention-deficit/hyperactivity disorder: retrospective case series». Ther Adv Psychopharmacol. 7 (11): 241–247. PMC 5638159. PMID 29090087. doi:10.1177/2045125317714193
Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M (setembro de 2013). «Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies». BMC Psychiatry. 13. 237 páginas. PMC 3852277. PMID 24074240. doi:10.1186/1471-244X-13-237
Steingard R, Taskiran S, Connor DF, Markowitz JS, Stein MA (junho de 2019). «New Formulations of Stimulants: An Update for Clinicians». J Child Adolesc Psychopharmacol. 29 (5): 324–339. PMC 7207053. PMID 31038360. doi:10.1089/cap.2019.0043
Froimowitz M, Patrick KS, Cody V (outubro de 1995). «Conformational analysis of methylphenidate and its structural relationship to other dopamine reuptake blockers such as CFT». Pharmaceutical Research. 12 (10): 1430–1434. PMID 8584475. doi:10.1023/A:1016262815984
Lakhan SE, Hagger-Johnson GE (outubro de 2007). «The impact of prescribed psychotropics on youth». Clinical Practice and Epidemiology in Mental Health. 3 (1): 21. PMC 2100041. PMID 17949504. doi:10.1186/1745-0179-3-21
Schoenfelder EN, Faraone SV, Kollins SH (junho de 2014). «Stimulant treatment of ADHD and cigarette smoking: A meta-analysis». Pediatrics. 133 (6): 1070–1080. PMC 4531271. PMID 24819571. doi:10.1542/peds.2014-0179
Wilens TE, Faraone SV, Biederman J, Gunawardene S (janeiro de 2003). «Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature». Pediatrics. 111 (1): 179–185. PMID 12509574. doi:10.1542/peds.111.1.179
Karlstad Ø, Zoëga H, Furu K, Bahmanyar S, Martikainen JE, Kieler H, Pottegård A (dezembro de 2016). «Use of drugs for ADHD among adults—a multinational study among 15.8 million adults in the Nordic countries». European Journal of Clinical Pharmacology. 72 (12): 1507–1514. PMC 5110707. PMID 27586399. doi:10.1007/s00228-016-2125-y
Bjarnadottir GD, Haraldsson HM, Rafnar BO, Sigurdsson E, Steingrimsson S, Johannsson M, Bragadottir H, Magnusson A (29 de novembro de 2016). «Prevalent intravenous abuse of methylphenidate among treatment-seeking patients with substance abuse disorders: a descriptive population-based study». Journal of Addiction Medicine. 9 (3): 188–194. PMC 4450903. PMID 25748561. doi:10.1097/ADM.0000000000000115
Ouellette EM (1991). «Legal issues in the treatment of children with attention deficit hyperactivity disorder». Journal of Child Neurology. 6 (Suppl): S68–S75. PMID 2002217. doi:10.1177/0883073891006001S08

drugabuse.gov

«Stimulant ADHD medications: Methylphenidate and amphetamines». Drugabuse.gov. NIDA InfoFacts. Consultado em 30 de abril de 2011. Cópia arquivada em 26 de março de 2010

drugbank.ca

«Methylphenidate». www.drugbank.ca. Consultado em 30 de janeiro de 2019. Arquivado do original em 31 de janeiro de 2019
«Methylphenidate». www.drugbank.ca. Consultado em 29 de agosto de 2019

drugs.com

«Methylphenidate Hydrochloride Monograph for Professionals». Drugs.com (em inglês). AHFS. Consultado em 19 de dezembro de 2018. Cópia arquivada em 19 de dezembro de 2018

elegislation.gov.hk

«Dangerous Drugs Ordinance». Hong Kong e-Legislation. 1438402701417-001. Consultado em 20 de março de 2019. Cópia arquivada em 28 de agosto de 2021

emedtv.com

adhd.emedtv.com

Emedtv. «Metadate CD». eMedTV: Health Information Brought To Life. Cópia arquivada em 10 de julho de 2011

escholarship.org

Chan YP, Swanson JM, Soldin SS, Thiessen JJ, Macleod SM, Logan W (julho de 1983). «Methylphenidate hydrochloride given with or before breakfast: II. Effects on plasma concentration of methylphenidate and ritalinic acid». Pediatrics. 72 (1): 56–59. PMID 6866592. doi:10.1542/peds.72.1.56. Consultado em 12 de dezembro de 2021. Cópia arquivada em 17 de dezembro de 2021

essentialmeds.org

list.essentialmeds.org

«eEML - Electronic Essential Medicines List». list.essentialmeds.org. Consultado em 26 de março de 2020

europa.eu

ema.europa.eu

«Tuzulby EPAR». European Medicines Agency (EMA). 12 de dezembro de 2024. Consultado em 16 de dezembro de 2024 Texto copiado desta fonte, cuja reprodução é autorizada mediante o devido crédito à fonte.

fda.gov

«Methylphenidate ADHD medications: Drug safety communication – risk of long-lasting erections». U.S. Food and Drug Administration (FDA). 17 de dezembro de 2013. Consultado em 17 de dezembro de 2013. Arquivado do original em 17 de dezembro de 2013
«FDA drug safety communication: Safety review update of medications used to treat attention-deficit / hyperactivity disorder (ADHD) in children and young adults». U.S. Food and Drug Administration (FDA). 20 de dezembro de 2011. Consultado em 4 de novembro de 2013. Cópia arquivada em 30 de outubro de 2013 Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA (novembro de 2011). «ADHD drugs and serious cardiovascular events in children and young adults». The New England Journal of Medicine. 365 (20): 1896–1904. PMC 4943074. PMID 22043968. doi:10.1056/NEJMoa1110212 «FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults». U.S. Food and Drug Administration (FDA). 15 de dezembro de 2011. Consultado em 4 de novembro de 2013. Cópia arquivada em 30 de outubro de 2013 Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV (dezembro de 2011). «ADHD medications and risk of serious cardiovascular events in young and middle-aged adults». JAMA. 306 (24): 2673–2683. PMC 3350308. PMID 22161946. doi:10.1001/jama.2011.1830
Methylphenidate transdermal system (MTS) (PDF) (safety summary). Noven Pharmaceuticals. 24 de outubro de 2005. NDA No. 21-514, Appendix 3. Consultado em 17 de janeiro de 2022. Arquivado do original (PDF) em 30 de setembro de 2007 – via U.S. Food and Drug Administration

accessdata.fda.gov

«FDA approved drug products». Drugs@FDA. US Food and Drug Administration. Consultado em 1 de outubro de 2016. Cópia arquivada em 2 de outubro de 2016 ^{[não consta na fonte citada]}
«Jornay PM Full Prescribing Information» (PDF). accessdata.fda.gov. FDA. Consultado em 27 de abril de 2024

fpnotebook.com

Moses S (26 de julho de 2009). «Methylphenidate». Family Practice Notebook. Consultado em 7 de agosto de 2012. Cópia arquivada em 14 de setembro de 2012

gesetze-im-internet.de

«Anlage III BtMG». Einzelnorm (em alemão). Consultado em 8 de janeiro de 2025

government.ru

«Decree of the Government of Russian Federation on 25 October 2014» (PDF). No. 1102. Consultado em 17 de outubro de 2019. Cópia arquivada (PDF) em 26 de março de 2015

hc-sc.gc.ca

webprod3.hc-sc.gc.ca

Apo‑methylphenidate SR (PDF) (product monograph). Apotex Inc. 31 de março de 2005. Consultado em 26 de julho de 2012 ^{[ligação inativa]}

health.gov.fj

«FIJI ISLANDS ILLICIT DRUGS CONTROL ACT 2004» (PDF). health.gov.fj. Consultado em 5 de agosto de 2023. Arquivado do original (PDF) em 13 de julho de 2018

incb.org

Green List: Annex to the annual statistical report on psychotropic substances (form P) (PDF) (Relatório) 23rd ed. Vienna International Centre, Austria: International Narcotics Board. Agosto de 2003. (1.63 MB). Consultado em 2 de março de 2006. Arquivado do original (PDF) em 31 de agosto de 2012

inchem.org

Heedes G, Ailakis J. «Methylphenidate hydrochloride (PIM 344)». INCHEM. International Programme on Chemical Safety. Consultado em 23 de junho de 2015. Cópia arquivada em 23 de junho de 2015

janssenmd.com

«Concerta product monograph» (PDF). Janssen Pharmaceuticals. Consultado em 4 de dezembro de 2016. Arquivado do original (PDF) em 28 de janeiro de 2017

jfponline.com

Mott TF, Leach L, Johnson L (2004). «Clinical inquiries. Is methylphenidate useful for treating adolescents with ADHD?». The Journal of Family Practice. 53 (8): 659–61. PMID 15298843. Consultado em 30 de abril de 2009. Cópia arquivada em 13 de julho de 2011

justice.gc.ca

laws-lois.justice.gc.ca

Controlled Drugs and Substances Act (Relatório). Laws. Department of Justice, Government of Canada. 25 de abril de 2017. S.C. 1996, c. 19. Consultado em 26 de abril de 2017. Cópia arquivada em 3 de abril de 2011

lagen.nu

«Narkotikastrafflag (1968:64)». Ministry of Justice. Consultado em 15 de janeiro de 2014. Cópia arquivada em 6 de outubro de 2013

mdedge.com

cdn.mdedge.com

Spiegel DR, Warren A, Takakura W, Servidio L, Leu N (janeiro de 2018). «Disorders of diminished motivation: What they are, and how to treat them» (PDF). Current Psychiatry. 17 (1): 10–18, 20

mohfw.nic.in

The Drugs and Cosmetics Rules (Relatório). Ministry of Health & Family Welfare. Government of India. 15 de agosto de 2013. pp. 729–730. Consultado em 5 de dezembro de 2016. Cópia arquivada em 8 de agosto de 2016 Parâmetro desconhecido |orig-date= ignorado (ajuda)

narcoticsindia.nic.in

Mehta R (26 de fevereiro de 2014). Drug Law Enforcement Field Officers' Hand Book (PDF) (Relatório). Narcotics Control Bureau, Ministry of Home Affairs. Government of India. p. 145. Consultado em 5 de dezembro de 2016. Arquivado do original (PDF) em 5 de março de 2017

nih.gov

ncbi.nlm.nih.gov

Bushe C, Day K, Reed V, Karlsdotter K, Berggren L, Pitcher A, Televantou F, Haynes V (maio de 2016). «A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients». Journal of Psychopharmacology. 30 (5): 444–458. PMID 27005307. doi:10.1177/0269881116636105
Hazell PL, Kohn MR, Dickson R, Walton RJ, Granger RE, Wyk GW (novembro de 2011). «Core ADHD symptom improvement with atomoxetine versus methylphenidate: a direct comparison meta-analysis». Journal of Attention Disorders. 15 (8): 674–683. PMID 20837981. doi:10.1177/1087054710379737
Hanwella R, Senanayake M, de Silva V (novembro de 2011). «Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis». BMC Psychiatry. 11 (1). 176 páginas. PMC 3229459. PMID 22074258. doi:10.1186/1471-244X-11-176
Rezaei G, Hosseini SA, Akbari Sari A, Olyaeemanesh A, Lotfi MH, Yassini M, Bidaki R, Nouri B (10 de fevereiro de 2016). «Comparative efficacy of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review and meta-analysis». Medical Journal of the Islamic Republic of Iran. 30. 325 páginas. PMC 4898838. PMID 27390695
Stuhec M, Lukić P, Locatelli I (fevereiro de 2019). «Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis». The Annals of Pharmacotherapy. 53 (2): 121–133. PMID 30117329. doi:10.1177/1060028018795703
Faraone SV, Pliszka SR, Olvera RL, Skolnik R, Biederman J (junho de 2001). «Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a reanalysis using drug-placebo and drug-drug response curve methodology». Journal of Child and Adolescent Psychopharmacology. 11 (2): 171–180. PMID 11436957. doi:10.1089/104454601750284081. ProQuest 204600452
Faraone SV, Biederman J, Roe C (outubro de 2002). «Comparative efficacy of Adderall and methylphenidate in attention-deficit/hyperactivity disorder: a meta-analysis». Journal of Clinical Psychopharmacology. 22 (5): 468–473. PMID 12352269. doi:10.1097/00004714-200210000-00005
Faraone SV, Buitelaar J (abril de 2010). «Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis». European Child & Adolescent Psychiatry. 19 (4): 353–364. PMID 19763664. doi:10.1007/s00787-009-0054-3
Arnsten AF, Li BM (2005). «Neurobiology of Executive Functions: Catecholamine Influences on Prefrontal Cortical Functions». Biological Psychiatry. 57: 1377–84. PMID 15950011. doi:10.1016/j.biopsych.2004.08.019
Fone KC, Nutt DJ (2005). «Stimulants: use and abuse in the treatment of ADD». Current Opinion in Pharmacology. 5 (1): 87–93. PMID 15661631. doi:10.1016/j.coph.2004.10.001
Capp PK, Pearl PL, Conlon C (2005). «Methylphenidate HCl: therapy for attention deficit hyperactivity disorder». Expert Rev Neurother. 5 (3): 325–31. PMID 15938665. doi:10.1586/14737175.5.3.325
Greenfield B, Hechman L (2005). «Treatment of attention deficit hyperactivity disorder in adults». Expert Rev Neurother. 5 (1): 107–21. PMID 15853481. doi:10.1586/14737175.5.1.107
Huss, Michael; Duhan, Praveen; Gandhi, Preetam; Chen, Chien-Wei; Spannhuth, Carsten; Kumar, Vinod (2 de junho de 2021). «Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity». Neuropsychiatric Disease and Treatment. 13: 1741–1751. PMC 5505611. PMID 28740389. doi:10.2147/NDT.S130444
Gilmore A, Milne R (2001). «Methylphenidate in children with hyperactivity: review and cost-utility analysis». Pharmacoepidemiol Drug Saf. 10 (2): 85–94. PMID 11499858. doi:10.1002/pds.564
Mott TF, Leach L, Johnson L (2004). «Clinical inquiries. Is methylphenidate useful for treating adolescents with ADHD?». The Journal of Family Practice. 53 (8): 659–61. PMID 15298843. Consultado em 30 de abril de 2009. Cópia arquivada em 13 de julho de 2011
Huang YS, Tsai MH (julho de 2011). «Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge». CNS Drugs. 25 (7): 539–554. PMID 21699268. doi:10.2165/11589380-000000000-00000
Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C (novembro de 2015). «Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)» (PDF). Cochrane Database Syst Rev. 11 (11): CD009885. PMID 26599576. doi:10.1002/14651858.CD009885.pub2. the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects.
Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S (fevereiro de 2002). «Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults». J. Am. Acad. Child Adolesc. Psychiatry. 41 (2 Suppl): 26S–49S. PMID 11833633. doi:10.1097/00004583-200202001-00003
Faraone SV, Wilens TE (2007). «Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion». J Clin Psychiatry. 68 Suppl 11 (11): 15–22. PMID 18307377. doi:10.4088/jcp.1107e28
Wilens TE, Faraone SV, Biederman J, Gunawardene S (2003). «Does Stimulant Therapy of Attention-Deficit/Hyperactivity Disorder Beget Later Substance Abuse? A Meta-analytic Review of the Literature». Pediatrics. 111 (1): 179–85. CiteSeerX 10.1.1.507.874. PMID 12509574. doi:10.1542/peds.111.1.179
Abelman DD (outubro de 2017). «Mitigating risks of students use of study drugs through understanding motivations for use and applying harm reduction theory: a literature review». Harm Reduction Journal. 14 (1). 68 páginas. PMC 5639593. PMID 28985738. doi:10.1186/s12954-017-0194-6
Vitiello B (outubro de 2001). «Psychopharmacology for young children: clinical needs and research opportunities». Pediatrics. 108 (4): 983–9. PMID 11581454. doi:10.1542/peds.108.4.983
Hermens DF, Rowe DL, Gordon E, Williams LM (2006). «Integrative neuroscience approach to predict ADHD stimulant response». Expert Review of Neurotherapeutics. 6 (5): 753–63. PMID 16734523. doi:10.1586/14737175.6.5.753
Management (1 de novembro de 2011). «ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents». Pediatrics. 128 (5): 1007–1022. ISSN 0031-4005. PMC 4500647. PMID 22003063. doi:10.1542/peds.2011-2654
Fry JM (fevereiro de 1998). «Treatment modalities for narcolepsy». Neurology. 50 (2 Suppl 1): S43-8. PMID 9484423. doi:10.1212/WNL.50.2_Suppl_1.S43
Mitler MM (dezembro de 1994). «Evaluation of treatment with stimulants in narcolepsy». Sleep. 17 (8 Suppl): S103-6. PMID 7701190. doi:10.1093/sleep/17.suppl_8.S103
Hart, Heledd; Radua, Joaquim; Nakao, Tomohiro; Mataix-Cols, David; Rubia, Katya (fevereiro de 2013). «Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects». JAMA psychiatry. 70 (2): 185–198. ISSN 2168-6238. PMID 23247506. doi:10.1001/jamapsychiatry.2013.277
Spencer, Thomas J.; Brown, Ariel; Seidman, Larry J.; Valera, Eve M.; Makris, Nikos; Lomedico, Alexandra; Faraone, Stephen V.; Biederman, Joseph (setembro de 2013). «Effect of Psychostimulants on Brain Structure and Function in ADHD: A Qualitative Literature Review of MRI-Based Neuroimaging Studies». The Journal of clinical psychiatry. 74 (9): 902–917. ISSN 0160-6689. PMC 3801446. PMID 24107764. doi:10.4088/JCP.12r08287
Frodl, T.; Skokauskas, N. (2012). «Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects». Acta Psychiatrica Scandinavica (em inglês). 125 (2): 114–126. ISSN 1600-0447. PMID 22118249. doi:10.1111/j.1600-0447.2011.01786.x
Markowitz JS, Patrick KS (junho de 2008). «Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: Does chirality matter?». Journal of Clinical Psychopharmacology. 28 (3 Suppl 2): S54–S61. PMID 18480678. doi:10.1097/JCP.0b013e3181733560
Williard RL, Middaugh LD, Zhu HJ, Patrick KS (fevereiro de 2007). «Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity». Behavioural Pharmacology. 18 (1): 39–51. PMID 17218796. doi:10.1097/fbp.0b013e3280143226
Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R (dezembro de 2006). «A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study». Journal of Child and Adolescent Psychopharmacology. 16 (6): 687–698. PMID 17201613. doi:10.1089/cap.2006.16.687
Markowitz JS, Logan BK, Diamond F, Patrick KS (1999). «Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion». Journal of Clinical Psychopharmacology. 19 (4): 362–6. PMID 10440465. doi:10.1097/00004714-199908000-00013
Markowitz JS, Logan BK, Diamond F, Patrick KS (1999). «Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion». Journal of Clinical Psychopharmacology. 19 (4): 362–6. PMID 10440465. doi:10.1097/00004714-199908000-00013
Iversen L (janeiro de 2006). «Neurotransmitter transporters and their impact on the development of psychopharmacology». British Journal of Pharmacology. 147 (Suppl 1): S82–S88. PMC 1760736. PMID 16402124. doi:10.1038/sj.bjp.0706428
Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (1 de janeiro de 2002). «Mechanism of action of methylphenidate: insights from PET imaging studies». Journal of Attention Disorders. 6 (Suppl 1): S31–S43. PMID 12685517. doi:10.1177/070674370200601s05
Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (1 de janeiro de 2002). «Mechanism of action of methylphenidate: insights from PET imaging studies». Journal of Attention Disorders. 6 (Suppl 1): S31–S43. PMID 12685517. doi:10.1177/070674370200601s05
Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (1 de janeiro de 2002). «Mechanism of action of methylphenidate: insights from PET imaging studies». Journal of Attention Disorders. 6 (Suppl 1): S31–S43. PMID 12685517. doi:10.1177/070674370200601s05
Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (1 de janeiro de 2002). «Mechanism of action of methylphenidate: insights from PET imaging studies». Journal of Attention Disorders. 6 (Suppl 1): S31–S43. PMID 12685517. doi:10.1177/070674370200601s05
Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (1 de janeiro de 2002). «Mechanism of action of methylphenidate: insights from PET imaging studies». Journal of Attention Disorders. 6 (Suppl 1): S31–S43. PMID 12685517. doi:10.1177/070674370200601s05
Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (1 de janeiro de 2002). «Mechanism of action of methylphenidate: insights from PET imaging studies». Journal of Attention Disorders. 6 (Suppl 1): S31–S43. PMID 12685517. doi:10.1177/070674370200601s05
Markowitz JS, DeVane CL, Ramamoorthy S, Zhu HJ (fevereiro de 2009). «The psychostimulant d-threo-(R,R)-methylphenidate binds as an agonist to the 5HT(1A) receptor». Die Pharmazie. 64 (2): 123–125. PMID 19322953
Volz TJ (dezembro de 2008). «Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidate». Current Neuropharmacology. 6 (4): 379–385. PMC 2701286. PMID 19587858. doi:10.2174/157015908787386041
Kimko HC, Cross JT, Abernethy DR (dezembro de 1999). «Pharmacokinetics and clinical effectiveness of methylphenidate». Clinical Pharmacokinetics. 37 (6): 457–470. PMID 10628897. doi:10.2165/00003088-199937060-00002
Chan YP, Swanson JM, Soldin SS, Thiessen JJ, Macleod SM, Logan W (julho de 1983). «Methylphenidate hydrochloride given with or before breakfast: II. Effects on plasma concentration of methylphenidate and ritalinic acid». Pediatrics. 72 (1): 56–59. PMID 6866592. doi:10.1542/peds.72.1.56. Consultado em 12 de dezembro de 2021. Cópia arquivada em 17 de dezembro de 2021
Lee L, Kepple J, Wang Y, Freestone S, Bakhtiar R, Wang Y, Hossain M (setembro de 2003). «Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce». Biopharmaceutics & Drug Disposition. 24 (6): 233–243. PMID 12973820. doi:10.1002/bdd.358
Lee L, Kepple J, Wang Y, Freestone S, Bakhtiar R, Wang Y, Hossain M (setembro de 2003). «Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce». Biopharmaceutics & Drug Disposition. 24 (6): 233–243. PMID 12973820. doi:10.1002/bdd.358
Nutt D, King LA, Saulsbury W, Blakemore C (março de 2007). «Development of a rational scale to assess the harm of drugs of potential misuse». Lancet. 369 (9566): 1047–1053. PMID 17382831. doi:10.1016/S0140-6736(07)60464-4
Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M (setembro de 2013). «Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies». Springer Science and Business Media LLC. BMC Psychiatry. 13 (1): 237. PMC 3852277. PMID 24074240. doi:10.1186/1471-244x-13-237
de Sousa A, Kalra G (janeiro de 2012). «Drug therapy of attention deficit hyperactivity disorder: current trends». Mens Sana Monographs. 10 (1): 45–69. PMC 3353606. PMID 22654382. doi:10.4103/0973-1229.87261 (inativo 2 November 2024) Verifique data em: |doi-incorrecto= (ajuda)
Jaanus SD (1992). «Ocular side effects of selected systemic drugs». Optometry Clinics. 2 (4): 73–96. PMID 1363080
Ross DC, Fischhoff J, Davenport B (janeiro de 2002). «Treatment of ADHD when tolerance to methylphenidate develops». Psychiatric Services. 53 (1). 102 páginas. PMID 11773663. doi:10.1176/appi.ps.53.1.102
Peterson BS, Trampush J, Maglione M, Bolshakova M, Rozelle M, Miles J, Pakdaman S, Brown M, Yagyu S, Motala A, Hempel S (abril de 2024). «Treatments for ADHD in Children and Adolescents: A Systematic Review». Pediatrics. 153 (4). PMID 38523592 Verifique |pmid= (ajuda). doi:10.1542/peds.2024-065787
Bron TI, Bijlenga D, Kasander MV, Spuijbroek AT, Beekman AT, Kooij JJ (junho de 2013). «Long-term relationship between methylphenidate and tobacco consumption and nicotine craving in adults with ADHD in a prospective cohort study». European Neuropsychopharmacology. 23 (6): 542–554. PMID 22809706. doi:10.1016/j.euroneuro.2012.06.004
Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Graham J, Taylor E, Sergeant J (março de 2013). «Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents». Journal of Child Psychology and Psychiatry, and Allied Disciplines. 54 (3): 227–246. PMID 23294014. doi:10.1111/jcpp.12036
Poulton A (agosto de 2005). «Growth on stimulant medication; clarifying the confusion: a review». Archives of Disease in Childhood. 90 (8): 801–806. PMC 1720538. PMID 16040876. doi:10.1136/adc.2004.056952
Hinshaw SP, Arnold LE (janeiro de 2015). «ADHD, Multimodal Treatment, and Longitudinal outcome: Evidence, paradox, and challenge». Wiley Interdisciplinary Reviews. Cognitive Science. 6 (1): 39–52. PMC 4280855. PMID 25558298. doi:10.1002/wcs.1324
Findling RL, Dinh S (março de 2014). «Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS)». CNS Drugs. 28 (3): 217–228. PMC 3933749. PMID 24532028. doi:10.1007/s40263-014-0141-y
Kraemer M, Uekermann J, Wiltfang J, Kis B (julho de 2010). «Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature». Clinical Neuropharmacology. 33 (4): 204–206. PMID 20571380. doi:10.1097/WNF.0b013e3181e29174
Wingo AP, Ghaemi SN (2008). «Frequency of stimulant treatment and of stimulant-associated mania/hypomania in bipolar disorder patients». Psychopharmacology Bulletin. 41 (4): 37–47. PMID 19015628
«FDA drug safety communication: Safety review update of medications used to treat attention-deficit / hyperactivity disorder (ADHD) in children and young adults». U.S. Food and Drug Administration (FDA). 20 de dezembro de 2011. Consultado em 4 de novembro de 2013. Cópia arquivada em 30 de outubro de 2013 Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA (novembro de 2011). «ADHD drugs and serious cardiovascular events in children and young adults». The New England Journal of Medicine. 365 (20): 1896–1904. PMC 4943074. PMID 22043968. doi:10.1056/NEJMoa1110212 «FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults». U.S. Food and Drug Administration (FDA). 15 de dezembro de 2011. Consultado em 4 de novembro de 2013. Cópia arquivada em 30 de outubro de 2013 Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV (dezembro de 2011). «ADHD medications and risk of serious cardiovascular events in young and middle-aged adults». JAMA. 306 (24): 2673–2683. PMC 3350308. PMID 22161946. doi:10.1001/jama.2011.1830
Gordon N (1999). «Attention deficit hyperactivity disorder: Possible causes and treatment». International Journal of Clinical Practice. 53 (7): 524–528. PMID 10692738. doi:10.1111/j.1742-1241.1999.tb11794.x
Storebø OJ, Pedersen N, Ramstad E, Kielsholm ML, Nielsen SS, Krogh HB, Moreira-Maia CR, Magnusson FL, Holmskov M, Gerner T, Skoog M, Rosendal S, Groth C, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Håkonsen SJ, Aagaard L, Simonsen E, Gluud C (maio de 2018). «Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies». The Cochrane Database of Systematic Reviews (Systematic Review). 5 (5): CD012069. PMC 6494554. PMID 29744873. doi:10.1002/14651858.CD012069.pub2
Spiller HA, Hays HL, Aleguas A (julho de 2013). «Overdose of drugs for attention-deficit hyperactivity disorder: Clinical presentation, mechanisms of toxicity, and management». CNS Drugs. 27 (7): 531–543. PMID 23757186. doi:10.1007/s40263-013-0084-8
Bruggisser M, Bodmer M, Liechti ME (2011). «Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets». Swiss Medical Weekly. 141: w13267. PMID 21984207. doi:10.4414/smw.2011.13267
Morton WA, Stockton GG (outubro de 2000). «Methylphenidate Abuse and Psychiatric Side Effects». Primary Care Companion to the Journal of Clinical Psychiatry. 2 (5): 159–164. PMC 181133. PMID 15014637. doi:10.4088/PCC.v02n0502
Auger RR, Goodman SH, Silber MH, Krahn LE, Pankratz VS, Slocumb NL (junho de 2005). «Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: A case-control study». Sleep. 28 (6): 667–672. PMID 16477952. doi:10.1093/sleep/28.6.667
Auger RR, Goodman SH, Silber MH, Krahn LE, Pankratz VS, Slocumb NL (junho de 2005). «Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: A case-control study». Sleep. 28 (6): 667–672. PMID 16477952. doi:10.1093/sleep/28.6.667
Ishii M, Tatsuzawa Y, Yoshino A, Nomura S (abril de 2008). «Serotonin syndrome induced by augmentation of SSRI with methylphenidate». Psychiatry and Clinical Neurosciences. 62 (2). 246 páginas. PMID 18412855. doi:10.1111/j.1440-1819.2008.01767.x
Türkoğlu S (2015). «Serotonin syndrome with sertraline and methylphenidate in an adolescent». Clinical Neuropharmacology. 38 (2): 65–6. PMID 25768857. doi:10.1097/WNF.0000000000000075
Park YM, Jung YK (maio de 2010). «Manic switch and serotonin syndrome induced by augmentation of paroxetine with methylphenidate in a patient with major depression». Progress in Neuro-Psychopharmacology & Biological Psychiatry. 34 (4): 719–20. PMID 20298736. doi:10.1016/j.pnpbp.2010.03.016
Bodner RA, Lynch T, Lewis L, Kahn D (fevereiro de 1995). «Serotonin syndrome». Neurology. 45 (2): 219–23. PMID 7854515. doi:10.1212/wnl.45.2.219
Feinberg, S. Shalom (novembro de 2004). «Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication». The Journal of Clinical Psychiatry. 65 (11): 1520–1524. ISSN 0160-6689. PMID 15554766
Israel, Joshua A. (10 de dezembro de 2015). «Combining Stimulants and Monoamine Oxidase Inhibitors: A Reexamination of the Literature and a Report of a New Treatment Combination». The Primary Care Companion for CNS Disorders. 17 (6). ISSN 2155-7772. PMC 4805402. PMID 27057401. doi:10.4088/PCC.15br01836
Shelton Clauson, Angela; Elliott, Ellie S.; Watson, Brian D.; Treacy, Journey (março de 2004). «Coadministration of phenelzine and methylphenidate for treatment-resistant depression». The Annals of Pharmacotherapy. 38 (3). 508 páginas. ISSN 1060-0280. PMID 14970373. doi:10.1345/aph.1D115
Thomas, Samantha J.; Shin, Mirae; McInnis, Melvin G.; Bostwick, Jolene R. (abril de 2015). «Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression». Pharmacotherapy. 35 (4): 433–449. ISSN 1875-9114. PMID 25884531. doi:10.1002/phar.1576
Patrick KS, González MA, Straughn AB, Markowitz JS (2005). «New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder». Expert Opinion on Drug Delivery. 2 (1): 121–43. PMID 16296740. doi:10.1517/17425247.2.1.121
Markowitz JS, DeVane CL, Boulton DW, Nahas Z, Risch SC, Diamond F, Patrick KS (2000). «Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol». Drug Metabolism and Disposition. 28 (6): 620–4. PMID 10820132
Patrick KS, Straughn AB, Minhinnett RR, Yeatts SD, Herrin AE, DeVane CL, Malcolm R, Janis GC, Markowitz JS (março de 2007). «Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics.». Clinical Pharmacology and Therapeutics. 81 (3): 346–53. PMC 3188424. PMID 17339864. doi:10.1038/sj.clpt.6100082
Bright, George M. (7 de maio de 2008). «Abuse of Medications Employed for the Treatment of ADHD: Results From a Large-Scale Community Survey». The Medscape Journal of Medicine. 111 páginas. PMC 2438483. PMID 18596945. Consultado em 22 de dezembro de 2021
Roberts SM, DeMott RP, James RC (1997). «Adrenergic modulation of hepatotoxicity». Drug Metab. Rev. 29 (1–2): 329–53. PMID 9187524. doi:10.3109/03602539709037587
Morton WA, Stockton, G. "Methylphenidate abuse and psychiatric side effects." Prim Care Companion J Clin Psychiatry. 2000 oct;2(5):159-64. PMID 15014637 Texto completo (PDF) Arquivado em 14 de novembro de 2006, no Wayback Machine.
Ruthirakuhan MT, Herrmann N, Abraham EH, Chan S, Lanctôt KL (maio de 2018). «Pharmacological interventions for apathy in Alzheimer's disease». Cochrane Database Syst Rev. 5 (5): CD012197. PMC 6494556. PMID 29727467. doi:10.1002/14651858.CD012197.pub2
Lee CW, Chen JY, Ko CC, Chuang MH, Tsai WW, Sun CK, Hung KC (dezembro de 2022). «Efficacy of methylphenidate for the treatment of apathy in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled studies». Psychopharmacology (Berl). 239 (12): 3743–3753. PMID 36243827. doi:10.1007/s00213-022-06261-y
Theleritis C, Siarkos K, Katirtzoglou E, Politis A (janeiro de 2017). «Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease : A systematic review across modalities». Journal of Geriatric Psychiatry and Neurology. 30 (1): 26–49. PMID 28248559. doi:10.1177/0891988716678684
Arnts H, van Erp WS, Lavrijsen JC, van Gaal S, Groenewegen HJ, van den Munckhof P (maio de 2020). «On the pathophysiology and treatment of akinetic mutism». Neurosci Biobehav Rev. 112: 270–278. PMID 32044373. doi:10.1016/j.neubiorev.2020.02.006
Rohde C, Polcwiartek C, Asztalos M, Nielsen J (janeiro de 2018). «Effectiveness of Prescription-Based CNS Stimulants on Hospitalization in Patients With Schizophrenia: A Nation-Wide Register Study». Schizophrenia Bulletin. 44 (1): 93–100. PMC 5768038. PMID 28379483. doi:10.1093/schbul/sbx043
Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J (2008). «Pharmacotherapy of methamphetamine addiction: an update». Substance Abuse. 29 (3): 31–49. PMC 2597382. PMID 19042205. doi:10.1080/08897070802218554
Grabowski J, Roache JD, Schmitz JM, Rhoades H, Creson D, Korszun A (dezembro de 1997). «Replacement medication for cocaine dependence: methylphenidate». Journal of Clinical Psychopharmacology. 17 (6): 485–488. PMID 9408812. doi:10.1097/00004714-199712000-00008
Shearer J (maio de 2008). «The principles of agonist pharmacotherapy for psychostimulant dependence». Drug and Alcohol Review. 27 (3): 301–308. PMID 18368612. doi:10.1080/09595230801927372
Villas-Boas CB, Chierrito D, Fernandez-Llimos F, Tonin FS, Sanches AC (março de 2019). «Pharmacological treatment of attention-deficit hyperactivity disorder comorbid with an anxiety disorder: a systematic review». Int Clin Psychopharmacol. 34 (2): 57–64. PMID 30422834. doi:10.1097/YIC.0000000000000243
Koyuncu A, İnce E, Ertekin E, Tükel R (2019). «Comorbidity in social anxiety disorder: diagnostic and therapeutic challenges». Drugs Context. 8. 212573 páginas. PMC 6448478. PMID 30988687. doi:10.7573/dic.212573
Pelissolo A, Abou Kassm S, Delhay L (dezembro de 2019). «Therapeutic strategies for social anxiety disorder: where are we now?». Expert Rev Neurother. 19 (12): 1179–1189. PMID 31502896. doi:10.1080/14737175.2019.1666713
Golubchik P, Sever J, Weizman A (julho de 2014). «Methylphenidate treatment in children with attention deficit hyperactivity disorder and comorbid social phobia». Int Clin Psychopharmacol. 29 (4): 212–215. PMC 4047304. PMID 24448460. doi:10.1097/YIC.0000000000000029
Koyuncu A, Çelebi F, Ertekin E, Kahn DA (maio de 2015). «Extended-release Methylphenidate Treatment and Outcomes in Comorbid Social Anxiety Disorder and Attention-deficit/Hyperactivity Disorder: 2 Case Reports». J Psychiatr Pract. 21 (3): 225–231. PMID 25955266. doi:10.1097/PRA.0000000000000070
Koyuncu A, Çelebi F, Ertekin E, Kök BE, Tükel R (novembro de 2017). «Extended-release methylphenidate monotherapy in patients with comorbid social anxiety disorder and adult attention-deficit/hyperactivity disorder: retrospective case series». Ther Adv Psychopharmacol. 7 (11): 241–247. PMC 5638159. PMID 29090087. doi:10.1177/2045125317714193
Koyuncu A, Çelebi F, Ertekin E, Kök BE, Tükel R (novembro de 2017). «Extended-release methylphenidate monotherapy in patients with comorbid social anxiety disorder and adult attention-deficit/hyperactivity disorder: retrospective case series». Ther Adv Psychopharmacol. 7 (11): 241–247. PMC 5638159. PMID 29090087. doi:10.1177/2045125317714193
Koyuncu A, Çelebi F, Ertekin E, Kök BE, Tükel R (novembro de 2017). «Extended-release methylphenidate monotherapy in patients with comorbid social anxiety disorder and adult attention-deficit/hyperactivity disorder: retrospective case series». Ther Adv Psychopharmacol. 7 (11): 241–247. PMC 5638159. PMID 29090087. doi:10.1177/2045125317714193
Koyuncu A, Çelebi F, Ertekin E, Kök BE, Tükel R (novembro de 2017). «Extended-release methylphenidate monotherapy in patients with comorbid social anxiety disorder and adult attention-deficit/hyperactivity disorder: retrospective case series». Ther Adv Psychopharmacol. 7 (11): 241–247. PMC 5638159. PMID 29090087. doi:10.1177/2045125317714193
Hosenbocus S, Chahal R (novembro de 2009). «A review of long-acting medications for ADHD in Canada». Journal of the Canadian Academy of Child and Adolescent Psychiatry. 18 (4): 331–339. PMC 2765387. PMID 19881943
Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M (setembro de 2013). «Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies». BMC Psychiatry. 13. 237 páginas. PMC 3852277. PMID 24074240. doi:10.1186/1471-244X-13-237
Steingard R, Taskiran S, Connor DF, Markowitz JS, Stein MA (junho de 2019). «New Formulations of Stimulants: An Update for Clinicians». J Child Adolesc Psychopharmacol. 29 (5): 324–339. PMC 7207053. PMID 31038360. doi:10.1089/cap.2019.0043
Froimowitz M, Patrick KS, Cody V (outubro de 1995). «Conformational analysis of methylphenidate and its structural relationship to other dopamine reuptake blockers such as CFT». Pharmaceutical Research. 12 (10): 1430–1434. PMID 8584475. doi:10.1023/A:1016262815984
Lakhan SE, Hagger-Johnson GE (outubro de 2007). «The impact of prescribed psychotropics on youth». Clinical Practice and Epidemiology in Mental Health. 3 (1): 21. PMC 2100041. PMID 17949504. doi:10.1186/1745-0179-3-21
Schoenfelder EN, Faraone SV, Kollins SH (junho de 2014). «Stimulant treatment of ADHD and cigarette smoking: A meta-analysis». Pediatrics. 133 (6): 1070–1080. PMC 4531271. PMID 24819571. doi:10.1542/peds.2014-0179
Wilens TE, Faraone SV, Biederman J, Gunawardene S (janeiro de 2003). «Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature». Pediatrics. 111 (1): 179–185. PMID 12509574. doi:10.1542/peds.111.1.179
Karlstad Ø, Zoëga H, Furu K, Bahmanyar S, Martikainen JE, Kieler H, Pottegård A (dezembro de 2016). «Use of drugs for ADHD among adults—a multinational study among 15.8 million adults in the Nordic countries». European Journal of Clinical Pharmacology. 72 (12): 1507–1514. PMC 5110707. PMID 27586399. doi:10.1007/s00228-016-2125-y
Bjarnadottir GD, Haraldsson HM, Rafnar BO, Sigurdsson E, Steingrimsson S, Johannsson M, Bragadottir H, Magnusson A (29 de novembro de 2016). «Prevalent intravenous abuse of methylphenidate among treatment-seeking patients with substance abuse disorders: a descriptive population-based study». Journal of Addiction Medicine. 9 (3): 188–194. PMC 4450903. PMID 25748561. doi:10.1097/ADM.0000000000000115
Ouellette EM (1991). «Legal issues in the treatment of children with attention deficit hyperactivity disorder». Journal of Child Neurology. 6 (Suppl): S68–S75. PMID 2002217. doi:10.1177/0883073891006001S08

dailymed.nlm.nih.gov

«Cotempla XR-ODT- methylphenidate tablet, orally disintegrating». DailyMed. 1 de julho de 2021. Consultado em 25 de maio de 2022. Cópia arquivada em 26 de maio de 2022
«Quillivant XR- methylphenidate hydrochloride suspension, extended release». DailyMed. 30 de junho de 2021. Consultado em 26 de maio de 2022. Cópia arquivada em 26 de maio de 2022
«Daytrana- methylphenidate patch». DailyMed. 15 de junho de 2021. Consultado em 26 de março de 2022. Cópia arquivada em 19 de março de 2022

nida.nih.gov

«Understanding drug abuse and addiction: What science says». US National Institute on Drug Addiction. 1 de fevereiro de 2019. Consultado em 11 de fevereiro de 2023

nih.gov

«New research helps explain ritalin's low abuse potential when taken as prescribed». NIH.gov. 29 de setembro de 1998. Consultado em 30 de abril de 2011. Cópia arquivada em 28 de maio de 2010

novartis.com

pharma.us.novartis.com

«Ritalin LA (metilfenidato cloridrato) cápsulas de liberação prolongada» (PDF). Novartis. Cópia arquivada (PDF) em 20 de julho de 2011

pfizermedicalinformation.com

«Quillichew ER (methylphenidate HCl extended-release chewable tablets CII)». Pfizer Medical Information (pfizermedicalinformation.com) (Nota de imprensa). EUA: Pfizer. Consultado em 16 de abril de 2017. Arquivado do original em 16 de abril de 2017

proquest.com

search.proquest.com

Faraone SV, Pliszka SR, Olvera RL, Skolnik R, Biederman J (junho de 2001). «Efficacy of Adderall and methylphenidate in attention deficit hyperactivity disorder: a reanalysis using drug-placebo and drug-drug response curve methodology». Journal of Child and Adolescent Psychopharmacology. 11 (2): 171–180. PMID 11436957. doi:10.1089/104454601750284081. ProQuest 204600452

psu.edu

citeseerx.ist.psu.edu

Wilens TE, Faraone SV, Biederman J, Gunawardene S (2003). «Does Stimulant Therapy of Attention-Deficit/Hyperactivity Disorder Beget Later Substance Abuse? A Meta-analytic Review of the Literature». Pediatrics. 111 (1): 179–85. CiteSeerX 10.1.1.507.874. PMID 12509574. doi:10.1542/peds.111.1.179

psychiatrist.com

Morton WA, Stockton, G. "Methylphenidate abuse and psychiatric side effects." Prim Care Companion J Clin Psychiatry. 2000 oct;2(5):159-64. PMID 15014637 Texto completo (PDF) Arquivado em 14 de novembro de 2006, no Wayback Machine.

psychiatryonline.org

ajp.psychiatryonline.org

Ver Charles Bradley, M.D., 1902–1979 Am J Psychiatry 155:968, julho de 1998.
Bradley C: "Behavior of children receiving Benzedrine". Am J Psychiatry. Nov 1937;94:577-85. Resumo (em inglês)

revistaencontro.com.br

Minas, Estado de; Minas, Estado de (2 de outubro de 2018). «Especialista fala sobre a falta de Ritalina no Brasil». Estado de Minas. Consultado em 22 de dezembro de 2021

rxbriefcase.com

«New product: Sandoz methylphenidate SR 20 mg» (PDF) (Nota de imprensa). Sandoz Canada Inc. 5 de maio de 2009. Consultado em 26 de julho de 2012. Cópia arquivada (PDF) em 3 de dezembro de 2012. An alternative to Ritalin‑SR from Novartis

rxlist.com

«Concerta (methylphenidate extended-release tablets)». RxList. Drug information: User reviews, side effects, drug interactions, and dosage. Consultado em 30 de abril de 2011. Cópia arquivada em 26 de março de 2011

sciencedirect.com

Schweren, Lizanne J. S.; de Zeeuw, Patrick; Durston, Sarah (1 de outubro de 2013). «MR imaging of the effects of methylphenidate on brain structure and function in Attention-Deficit/Hyperactivity Disorder». European Neuropsychopharmacology. 23 (10): 1151–1164. ISSN 0924-977X. doi:10.1016/j.euroneuro.2012.10.014

sdu.dk

findresearcher.sdu.dk

Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C (novembro de 2015). «Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)» (PDF). Cochrane Database Syst Rev. 11 (11): CD009885. PMID 26599576. doi:10.1002/14651858.CD009885.pub2. the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects.

semanticscholar.org

Vitiello B (outubro de 2001). «Psychopharmacology for young children: clinical needs and research opportunities». Pediatrics. 108 (4): 983–9. PMID 11581454. doi:10.1542/peds.108.4.983

statutelaw.gov.uk

http://www.statutelaw.gov.uk/content.aspx?LegType=All+Legislation&title=The+Misuse+of+Drugs+Act+1971&searchEnacted=0&extentMatchOnly=0&confersPower=0&blanketAmendment=0&sortAlpha=0&TYPE=QS&PageNumber=1&NavFrom=0&parentActiveTextDocId=1367412&ActiveTextDocId=1367471&filesize=1699 |section-url= missing title (ajuda). Misuse of Drugs Act (c. 38) (Relatório). Office of Public Sector Information. 1971. Consultado em 15 de junho de 2009. Cópia arquivada em 28 de agosto de 2021
http://www.statutelaw.gov.uk/content.aspx?LegType=All+Legislation&title=The+Misuse+of+Drugs+Act+1971&searchEnacted=0&extentMatchOnly=0&confersPower=0&blanketAmendment=0&sortAlpha=0&TYPE=QS&PageNumber=1&NavFrom=0&parentActiveTextDocId=1367412&ActiveTextDocId=1367471&filesize=1699 |section-url= missing title (ajuda). Misuse of Drugs Act (c. 38) (Relatório). Office of Public Sector Information. 1971. Consultado em 15 de junho de 2009. Cópia arquivada em 28 de agosto de 2021

uic.edu

psych.uic.edu

«Education / training». Illinois DocAssist. Clinical resources. Chicago, IL: University of Illinois. Consultado em 26 de julho de 2012. Arquivado do original em 1 de janeiro de 2013. Ritalin‑SR, methylphenidate SR, Methylin ER, and Metadate ER are the same formulation and have the same drug delivery system

uol.com.br

drauziovarella.uol.com.br

Varella, Dr Drauzio (2 de setembro de 2014). «Ritalina para TDAH precisa ser prescrita com muito critério». Drauzio Varella. Consultado em 27 de setembro de 2019

vidal.fr

«TDAH : la prescription de méthylphénidate peut désormais être initiée en villexxxxxxxxx». VIDAL (em francês)

web.archive.org

«Methylphenidate Hydrochloride Monograph for Professionals». Drugs.com (em inglês). AHFS. Consultado em 19 de dezembro de 2018. Cópia arquivada em 19 de dezembro de 2018
«Methylphenidate». www.drugbank.ca. Consultado em 30 de janeiro de 2019. Arquivado do original em 31 de janeiro de 2019
Mott TF, Leach L, Johnson L (2004). «Clinical inquiries. Is methylphenidate useful for treating adolescents with ADHD?». The Journal of Family Practice. 53 (8): 659–61. PMID 15298843. Consultado em 30 de abril de 2009. Cópia arquivada em 13 de julho de 2011
«Stimulants for Attention Deficit Hyperactivity Disorder». WebMD. Healthwise. 12 de abril de 2010. Consultado em 12 de novembro de 2013. Arquivado do original em 13 de novembro de 2013
Chan YP, Swanson JM, Soldin SS, Thiessen JJ, Macleod SM, Logan W (julho de 1983). «Methylphenidate hydrochloride given with or before breakfast: II. Effects on plasma concentration of methylphenidate and ritalinic acid». Pediatrics. 72 (1): 56–59. PMID 6866592. doi:10.1542/peds.72.1.56. Consultado em 12 de dezembro de 2021. Cópia arquivada em 17 de dezembro de 2021
«Cotempla XR-ODT- methylphenidate tablet, orally disintegrating». DailyMed. 1 de julho de 2021. Consultado em 25 de maio de 2022. Cópia arquivada em 26 de maio de 2022
«Quillivant XR- methylphenidate hydrochloride suspension, extended release». DailyMed. 30 de junho de 2021. Consultado em 26 de maio de 2022. Cópia arquivada em 26 de maio de 2022
«Ritalin LA (metilfenidato cloridrato) cápsulas de liberação prolongada» (PDF). Novartis. Cópia arquivada (PDF) em 20 de julho de 2011
«Methylphenidate ADHD medications: Drug safety communication – risk of long-lasting erections». U.S. Food and Drug Administration (FDA). 17 de dezembro de 2013. Consultado em 17 de dezembro de 2013. Arquivado do original em 17 de dezembro de 2013
«FDA drug safety communication: Safety review update of medications used to treat attention-deficit / hyperactivity disorder (ADHD) in children and young adults». U.S. Food and Drug Administration (FDA). 20 de dezembro de 2011. Consultado em 4 de novembro de 2013. Cópia arquivada em 30 de outubro de 2013 Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA (novembro de 2011). «ADHD drugs and serious cardiovascular events in children and young adults». The New England Journal of Medicine. 365 (20): 1896–1904. PMC 4943074. PMID 22043968. doi:10.1056/NEJMoa1110212 «FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in adults». U.S. Food and Drug Administration (FDA). 15 de dezembro de 2011. Consultado em 4 de novembro de 2013. Cópia arquivada em 30 de outubro de 2013 Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham TC, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN, Ray WA, Selby JV (dezembro de 2011). «ADHD medications and risk of serious cardiovascular events in young and middle-aged adults». JAMA. 306 (24): 2673–2683. PMC 3350308. PMID 22161946. doi:10.1001/jama.2011.1830
«Daytrana- methylphenidate patch». DailyMed. 15 de junho de 2021. Consultado em 26 de março de 2022. Cópia arquivada em 19 de março de 2022
Heedes G, Ailakis J. «Methylphenidate hydrochloride (PIM 344)». INCHEM. International Programme on Chemical Safety. Consultado em 23 de junho de 2015. Cópia arquivada em 23 de junho de 2015
«Concerta product monograph» (PDF). Janssen Pharmaceuticals. Consultado em 4 de dezembro de 2016. Arquivado do original (PDF) em 28 de janeiro de 2017
Morton WA, Stockton, G. "Methylphenidate abuse and psychiatric side effects." Prim Care Companion J Clin Psychiatry. 2000 oct;2(5):159-64. PMID 15014637 Texto completo (PDF) Arquivado em 14 de novembro de 2006, no Wayback Machine.
«Education / training». Illinois DocAssist. Clinical resources. Chicago, IL: University of Illinois. Consultado em 26 de julho de 2012. Arquivado do original em 1 de janeiro de 2013. Ritalin‑SR, methylphenidate SR, Methylin ER, and Metadate ER are the same formulation and have the same drug delivery system
«New product: Sandoz methylphenidate SR 20 mg» (PDF) (Nota de imprensa). Sandoz Canada Inc. 5 de maio de 2009. Consultado em 26 de julho de 2012. Cópia arquivada (PDF) em 3 de dezembro de 2012. An alternative to Ritalin‑SR from Novartis
«FDA approved drug products». Drugs@FDA. US Food and Drug Administration. Consultado em 1 de outubro de 2016. Cópia arquivada em 2 de outubro de 2016 ^{[não consta na fonte citada]}
«Aptensio XR Prescribing Information» (PDF). Consultado em 15 de abril de 2017. Cópia arquivada (PDF) em 2 de fevereiro de 2017
Moses S (26 de julho de 2009). «Methylphenidate». Family Practice Notebook. Consultado em 7 de agosto de 2012. Cópia arquivada em 14 de setembro de 2012
«Daytrana transdermal». WebMD. Consultado em 11 de junho de 2015. Cópia arquivada em 11 de junho de 2015
«Quillichew ER (methylphenidate HCl extended-release chewable tablets CII)». Pfizer Medical Information (pfizermedicalinformation.com) (Nota de imprensa). EUA: Pfizer. Consultado em 16 de abril de 2017. Arquivado do original em 16 de abril de 2017
«Concerta (methylphenidate extended-release tablets)». RxList. Drug information: User reviews, side effects, drug interactions, and dosage. Consultado em 30 de abril de 2011. Cópia arquivada em 26 de março de 2011
Emedtv. «Metadate CD». eMedTV: Health Information Brought To Life. Cópia arquivada em 10 de julho de 2011
Methylphenidate transdermal system (MTS) (PDF) (safety summary). Noven Pharmaceuticals. 24 de outubro de 2005. NDA No. 21-514, Appendix 3. Consultado em 17 de janeiro de 2022. Arquivado do original (PDF) em 30 de setembro de 2007 – via U.S. Food and Drug Administration
Green List: Annex to the annual statistical report on psychotropic substances (form P) (PDF) (Relatório) 23rd ed. Vienna International Centre, Austria: International Narcotics Board. Agosto de 2003. (1.63 MB). Consultado em 2 de março de 2006. Arquivado do original (PDF) em 31 de agosto de 2012
«Poisons Standard 2012 as amended made under paragraph 52D(2)(a) of the Therapeutic Goods Act 1989». Therapeutic Goods Administration. 27 de novembro de 2014. Consultado em 28 de junho de 2015. Cópia arquivada em 1 de julho de 2015
Controlled Drugs and Substances Act (Relatório). Laws. Department of Justice, Government of Canada. 25 de abril de 2017. S.C. 1996, c. 19. Consultado em 26 de abril de 2017. Cópia arquivada em 3 de abril de 2011
«FIJI ISLANDS ILLICIT DRUGS CONTROL ACT 2004» (PDF). health.gov.fj. Consultado em 5 de agosto de 2023. Arquivado do original (PDF) em 13 de julho de 2018
«Dangerous Drugs Ordinance». Hong Kong e-Legislation. 1438402701417-001. Consultado em 20 de março de 2019. Cópia arquivada em 28 de agosto de 2021
The Drugs and Cosmetics Rules (Relatório). Ministry of Health & Family Welfare. Government of India. 15 de agosto de 2013. pp. 729–730. Consultado em 5 de dezembro de 2016. Cópia arquivada em 8 de agosto de 2016 Parâmetro desconhecido |orig-date= ignorado (ajuda)
Mehta R (26 de fevereiro de 2014). Drug Law Enforcement Field Officers' Hand Book (PDF) (Relatório). Narcotics Control Bureau, Ministry of Home Affairs. Government of India. p. 145. Consultado em 5 de dezembro de 2016. Arquivado do original (PDF) em 5 de março de 2017
«Decree of the Government of Russian Federation on 25 October 2014» (PDF). No. 1102. Consultado em 17 de outubro de 2019. Cópia arquivada (PDF) em 26 de março de 2015
«Narkotikastrafflag (1968:64)». Ministry of Justice. Consultado em 15 de janeiro de 2014. Cópia arquivada em 6 de outubro de 2013
http://www.statutelaw.gov.uk/content.aspx?LegType=All+Legislation&title=The+Misuse+of+Drugs+Act+1971&searchEnacted=0&extentMatchOnly=0&confersPower=0&blanketAmendment=0&sortAlpha=0&TYPE=QS&PageNumber=1&NavFrom=0&parentActiveTextDocId=1367412&ActiveTextDocId=1367471&filesize=1699 |section-url= missing title (ajuda). Misuse of Drugs Act (c. 38) (Relatório). Office of Public Sector Information. 1971. Consultado em 15 de junho de 2009. Cópia arquivada em 28 de agosto de 2021
http://www.statutelaw.gov.uk/content.aspx?LegType=All+Legislation&title=The+Misuse+of+Drugs+Act+1971&searchEnacted=0&extentMatchOnly=0&confersPower=0&blanketAmendment=0&sortAlpha=0&TYPE=QS&PageNumber=1&NavFrom=0&parentActiveTextDocId=1367412&ActiveTextDocId=1367471&filesize=1699 |section-url= missing title (ajuda). Misuse of Drugs Act (c. 38) (Relatório). Office of Public Sector Information. 1971. Consultado em 15 de junho de 2009. Cópia arquivada em 28 de agosto de 2021
Moscibrodzki P, Katz C (8 de dezembro de 2018). Application for inclusion to the 22nd expert committee on the selection and use of essential medicines: Methylphenidate hydrochloride (PDF) (Relatório). World Health Organization. Consultado em 16 de novembro de 2019. Cópia arquivada (PDF) em 6 de agosto de 2020
«New research helps explain ritalin's low abuse potential when taken as prescribed». NIH.gov. 29 de setembro de 1998. Consultado em 30 de abril de 2011. Cópia arquivada em 28 de maio de 2010
«Stimulant ADHD medications: Methylphenidate and amphetamines». Drugabuse.gov. NIDA InfoFacts. Consultado em 30 de abril de 2011. Cópia arquivada em 26 de março de 2010

webmd.com

«Stimulants for Attention Deficit Hyperactivity Disorder». WebMD. Healthwise. 12 de abril de 2010. Consultado em 12 de novembro de 2013. Arquivado do original em 13 de novembro de 2013
«Daytrana transdermal». WebMD. Consultado em 11 de junho de 2015. Cópia arquivada em 11 de junho de 2015

who.int

Moscibrodzki P, Katz C (8 de dezembro de 2018). Application for inclusion to the 22nd expert committee on the selection and use of essential medicines: Methylphenidate hydrochloride (PDF) (Relatório). World Health Organization. Consultado em 16 de novembro de 2019. Cópia arquivada (PDF) em 6 de agosto de 2020

wiley.com

onlinelibrary.wiley.com

Frodl, T.; Skokauskas, N. (2012). «Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects». Acta Psychiatrica Scandinavica (em inglês). 125 (2): 114–126. ISSN 1600-0447. PMID 22118249. doi:10.1111/j.1600-0447.2011.01786.x

windows.net

mhraproductsproduction.blob.core.windows.net

«UK Report on Ritalin». p. 9. Consultado em 9 de janeiro de 2024

worldcat.org

Management (1 de novembro de 2011). «ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents». Pediatrics. 128 (5): 1007–1022. ISSN 0031-4005. PMC 4500647. PMID 22003063. doi:10.1542/peds.2011-2654
Neinstein, Lawrence (2009). Handbook of adolescent health care. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. ISBN 978-0-7817-9020-8. OCLC 226304727 ^:722
Hart, Heledd; Radua, Joaquim; Nakao, Tomohiro; Mataix-Cols, David; Rubia, Katya (fevereiro de 2013). «Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects». JAMA psychiatry. 70 (2): 185–198. ISSN 2168-6238. PMID 23247506. doi:10.1001/jamapsychiatry.2013.277
Spencer, Thomas J.; Brown, Ariel; Seidman, Larry J.; Valera, Eve M.; Makris, Nikos; Lomedico, Alexandra; Faraone, Stephen V.; Biederman, Joseph (setembro de 2013). «Effect of Psychostimulants on Brain Structure and Function in ADHD: A Qualitative Literature Review of MRI-Based Neuroimaging Studies». The Journal of clinical psychiatry. 74 (9): 902–917. ISSN 0160-6689. PMC 3801446. PMID 24107764. doi:10.4088/JCP.12r08287
Frodl, T.; Skokauskas, N. (2012). «Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects». Acta Psychiatrica Scandinavica (em inglês). 125 (2): 114–126. ISSN 1600-0447. PMID 22118249. doi:10.1111/j.1600-0447.2011.01786.x
Schweren, Lizanne J. S.; de Zeeuw, Patrick; Durston, Sarah (1 de outubro de 2013). «MR imaging of the effects of methylphenidate on brain structure and function in Attention-Deficit/Hyperactivity Disorder». European Neuropsychopharmacology. 23 (10): 1151–1164. ISSN 0924-977X. doi:10.1016/j.euroneuro.2012.10.014
Feinberg, S. Shalom (novembro de 2004). «Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication». The Journal of Clinical Psychiatry. 65 (11): 1520–1524. ISSN 0160-6689. PMID 15554766
Israel, Joshua A. (10 de dezembro de 2015). «Combining Stimulants and Monoamine Oxidase Inhibitors: A Reexamination of the Literature and a Report of a New Treatment Combination». The Primary Care Companion for CNS Disorders. 17 (6). ISSN 2155-7772. PMC 4805402. PMID 27057401. doi:10.4088/PCC.15br01836
Shelton Clauson, Angela; Elliott, Ellie S.; Watson, Brian D.; Treacy, Journey (março de 2004). «Coadministration of phenelzine and methylphenidate for treatment-resistant depression». The Annals of Pharmacotherapy. 38 (3). 508 páginas. ISSN 1060-0280. PMID 14970373. doi:10.1345/aph.1D115
Thomas, Samantha J.; Shin, Mirae; McInnis, Melvin G.; Bostwick, Jolene R. (abril de 2015). «Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression». Pharmacotherapy. 35 (4): 433–449. ISSN 1875-9114. PMID 25884531. doi:10.1002/phar.1576